SENSEI BIOTHERAPEUTICS, INC. : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)

Item 7.01 Regulation FD Disclosure.

On June 28, 2021, Sensei Biotherapeutics, Inc. (the "Company") issued a press release announcing the prioritization of its next-generation, multi-antigenic ImmunoPhage platform, monoclonal antibody and nanobody programs, as well as information regarding a conference call to discuss these company updates. The Company's press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The information in this Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1, is being furnished pursuant to Item 7.01 and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act") or otherwise subject to the liabilities of that section, and it shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or under the Exchange Act, whether made before or after the date hereof, except as expressly set forth by specific reference in such filing to this item of this report.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits



                Exhibit
                Number              Exhibit Description

                99.1        Press Release, dated June 28, 2021




                                       2

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses